GRAIL appoints Sarah Krevans to Board of Directors, effective Oct 21

GRAIL, Inc.

Krevans appointed as Class II director; will serve on Audit, Compensation, and Nominating & Governance Committees.
Receives annual cash retainer of $50,000 plus committee retainers ($10k Audit, $7.5k Comp, $5k NCG), and initial grant of 31,055 RSUs vesting over 3 years.
Krevans previously President and CEO of Sutter Health; Board now has 5 directors, 4 independent.
Company disclosed ~$1.6M in 2023 payments to Sutter Institute for Medical Research for PATHFINDER 2 study.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Sarah Krevans

Director

GRAL · GRAIL, Inc.

Effective: 2024-10-21
Filed: October 22, 2024, 7:59 PM ET

On October 21, 2024, the Board of Directors (the “Board”) of GRAIL, Inc. (the “Company”) appointed Sarah Krevans to the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sarah Krevans was appointed as Director at GRAIL, Inc..

Action: appointed
Role: Director

Exact text from the filing

On October 21, 2024, the Board of Directors (the “Board”) of GRAIL, Inc. (the “Company”) appointed Sarah Krevans to the Board, effective immediately.

View on SEC.gov

GRAIL, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-043305

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.